Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir LA Q4M for HIV PrEP
NCT06741397Phase 2Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Dec 2024; status: active, not recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06741397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741397.